Adicet Bio, Inc. announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis. Fast Track Designation is a process designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.335 USD | -0.37% | -1.84% | -29.37% |
06-24 | Adicet Bio Shares Rise 4% on FDA Clearance of IND Application for ADI-270 | DJ |
06-24 | Adicet Bio Receives FDA Clearance for ADI-270 New Drug Application | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.37% | 110M | |
+21.26% | 46.93B | |
+37.63% | 39.08B | |
-8.13% | 38.48B | |
+29.22% | 31.01B | |
-13.75% | 26.14B | |
+10.99% | 25.88B | |
+36.32% | 12.53B | |
-6.91% | 11.36B | |
-12.80% | 10.65B |
- Stock Market
- Equities
- ACET Stock
- News Adicet Bio, Inc.
- Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis